Bhutan
Tuberculosis profile
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.1 (0.062–0.15) 14 (8.4–21)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.52 (0.42–0.71)
Prevalence  (includes HIV+TB) 1.7 (0.58–3.3) 225 (79–446)
Incidence  (includes HIV+TB) 1.3 (1.1–1.5) 180 (154–207)
Incidence (HIV+TB only) 0.024 (0.021–0.028) 3.3 (2.8–3.8)
Case detection, all forms (%) 85 (73–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 420 (39) Relapse 64 (81)
Smear-negative 127 (12) Treatment after failure 10 (13)
Smear-unknown / not done 0 (0) Treatment after default 5 (6)
Extrapulmonary 519 (49) Other    
Other          
Total new 1 066   Total retreatment 79  
           
Other (history unknown)          
Total new and relapse 1 130   Total cases notified 1 145  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.0 1.0 0.8
Age < 15 12 10 20
Laboratories 2012
Smear (per 100 000 population) 4.7
Culture (per 5 million population) 6.7
Drug susceptibility testing (per 5 million population) 6.7
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 91   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 92  
Retreatment 76  
TB/HIV 2012 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.6–2.8) 16 (11–21)
MDR-TB cases among notified pulmonary
TB cases
12 (9–15) 13 (9–17)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 52 (12%) 2 (3%) 94
Laboratory-confirmed MDR-TB cases 5 0 16
Patients started on MDR-TB treatment     11
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 4%
% Funded internationally 99%
% Unfunded <1%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-18 Data: www.who.int/tb/data